Skip to main content

Table 2 Demographics and treatment dosages

From: Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program

 

Randomized withdrawal study

Extension study

 

Nonrandomized

Randomized

All patients

n = 96

n = 20

n = 57

Age, years, mean (SD)

15.7 (1.3)

15.0 (1.6)

15.4 (1.4)

Female, n (%)

86 (89.6)

12 (60.0)

50 (87.7)

White, n (%)

86 (89.6)

14 (70.0)

51 (89.5)

BMI, kg/m2, mean (SD)

25.8 (6.2)

24.8 (5.3)

26.1 (6.3)

Maximum tolerated dosea

   

50 mg/day

6 (6.3)

1 (7.1)a

3 (5.3)

75 mg/day

9 (9.4)

4 (28.6)a

8 (14.0)

100 mg/day

69 (71.9)

9 (64.3)a

46 (80.7)

No available MTD data

12 (12.5)

0a

0

  1. aAs reported in the milnacipran group only (n = 14)
  2. BMI = body mass index, MTD = maximum tolerated dose, SD = standard deviation
  3. MTD = maximum tolerated dose